SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-24-010960
Filing Date
2024-03-13
Accepted
2024-03-13 17:03:29
Documents
6
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2023proxystatement.htm DEF 14A 561999
2 GRAPHIC ajbackgroundpicture.jpg GRAPHIC 10605
3 GRAPHIC chart-c0a7257dbd8c4d56be2.jpg GRAPHIC 100988
4 GRAPHIC cumberlandlogoa02a01.jpg GRAPHIC 12534
5 GRAPHIC cumberlandpharmalogoa01.jpg GRAPHIC 37721
6 GRAPHIC xa01.jpg GRAPHIC 2405
  Complete submission text file 0001628280-24-010960.txt   789952
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33637 | Film No.: 24746859
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)